Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Hypoglycemic effect of bitter melon compared with metformin in newly diagnosed type 2 diabetes patients.

Fuangchan A, Sonthisombat P, Seubnukarn T, Chanouan R, Chotchaisuwat P, Sirigulsatien V, Ingkaninan K, Plianbangchang P, Haines ST.

J Ethnopharmacol. 2011 Mar 24;134(2):422-8. doi: 10.1016/j.jep.2010.12.045. Epub 2011 Jan 4.

PMID:
21211558
2.

Serum sialic acid changes in non-insulin-dependant diabetes mellitus (NIDDM) patients following bitter melon (Momordica charantia) and rosiglitazone (Avandia) treatment.

Inayat-ur-Rahman, Malik SA, Bashir M, Khan R, Iqbal M.

Phytomedicine. 2009 May;16(5):401-5. doi: 10.1016/j.phymed.2009.01.001. Epub 2009 Apr 10.

PMID:
19362455
3.

Bitter melon (Momordica charantia): a review of efficacy and safety.

Basch E, Gabardi S, Ulbricht C.

Am J Health Syst Pharm. 2003 Feb 15;60(4):356-9. Review.

PMID:
12625217
4.

Evaluation of the efficacy of bitter gourd (momordica charantia) as an oral hypoglycemic agent--a randomized controlled clinical trial.

John AJ, Cherian R, Subhash HS, Cherian AM.

Indian J Physiol Pharmacol. 2003 Jul;47(3):363-5. No abstract available.

PMID:
14723327
5.

The effect of Momordica charantia capsule preparation on glycemic control in type 2 diabetes mellitus needs further studies.

Dans AM, Villarruz MV, Jimeno CA, Javelosa MA, Chua J, Bautista R, Velez GG.

J Clin Epidemiol. 2007 Jun;60(6):554-9. Epub 2006 Nov 13.

PMID:
17493509
6.

Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes.

Schwartz S, Fonseca V, Berner B, Cramer M, Chiang YK, Lewin A.

Diabetes Care. 2006 Apr;29(4):759-64.

PMID:
16567811
9.
10.
11.

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.

Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P; Sitagliptin Study 035 Group.

Diabetes Obes Metab. 2007 Sep;9(5):733-45. Epub 2007 Jun 26.

PMID:
17593236
12.

Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial.

Derosa G, Gaddi AV, Piccinni MN, Salvadeo S, Ciccarelli L, Fogari E, Ghelfi M, Ferrari I, Cicero AF.

Diabetes Obes Metab. 2006 Mar;8(2):197-205.

PMID:
16448524
13.
14.
18.

Lower hypoglycemic but higher antiatherogenic effects of bitter melon than glibenclamide in type 2 diabetic patients.

Inayat U Rahman, Khan RU, Khalil Ur Rahman, Bashir M.

Nutr J. 2015 Jan 26;14:13. doi: 10.1186/1475-2891-14-13.

20.

Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.

Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF.

J Clin Pharm Ther. 2006 Aug;31(4):375-83.

PMID:
16882108

Supplemental Content

Support Center